Literature DB >> 12613191

Growth, survival and migration: the Trk to cancer.

Joshua B Rubin1, Rosalind A Segal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12613191     DOI： 10.1007/0-306-48158-8_1

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  19 in total

Review 1.  Neurotrophins and the immune system.

Authors:  José A Vega; Olivia García-Suárez; Jonas Hannestad; Marta Pérez-Pérez; Antonino Germanà
Journal:  J Anat       Date:  2003-07       Impact factor: 2.610

Review 2.  TRK Inhibitors: Clinical Development of Larotrectinib.

Authors:  Munveer S Bhangoo; Darren Sigal
Journal:  Curr Oncol Rep       Date:  2019-02-04       Impact factor: 5.075

Review 3.  Current and emerging biomarkers in metastatic colorectal cancer.

Authors:  M K C Lee; J M Loree
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

Review 4.  LG-ESSs and HG-ESSs: underlying molecular alterations and potential therapeutic strategies.

Authors:  Chunhui Li; Chunhong Wang
Journal:  J Zhejiang Univ Sci B       Date:  2021-08-15       Impact factor: 3.066

5.  TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells.

Authors:  Siyang Zhang; Dawei Guo; Wenting Luo; Qingfu Zhang; Ying Zhang; Chunyan Li; Yao Lu; Zeshi Cui; Xueshan Qiu
Journal:  BMC Cancer       Date:  2010-02-16       Impact factor: 4.430

6.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Authors:  Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins
Journal:  Lancet Oncol       Date:  2018-03-29       Impact factor: 41.316

Review 7.  Chiral kinase inhibitors.

Authors:  Jian-kang Jiang; Min Shen; Craig J Thomas; Mathew B Boxer
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas.

Authors:  Nathan A Dahl; Andrew M Donson; Bridget Sanford; Dong Wang; Faye M Walker; Ahmed Gilani; Nicholas K Foreman; Christopher L Tinkle; Suzanne J Baker; Lindsey M Hoffman; Sujatha Venkataraman; Rajeev Vibhakar
Journal:  J Neuropathol Exp Neurol       Date:  2021-03-22       Impact factor: 3.685

9.  EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.

Authors:  Xiaohe Dang; Tao Xiang; Can Zhao; Hao Tang; Pengfei Cui
Journal:  Front Med (Lausanne)       Date:  2022-04-28

10.  Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors.

Authors:  Limin Zhu; Brian Hobbs; Jason Roszik; Vijaykumar Holla; David S Hong
Journal:  Invest New Drugs       Date:  2021-08-02       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.